Yahoo
OTC Markets OTCPK - Delayed Quote USD

Numinus Wellness Inc. (NUMIF)

0.0170 -0.0067 (-28.27%)
As of 12:11:12 PM EST. Market Open.
Chart Range Bar
Loading chart for NUMIF
  • Previous Close 0.0237
  • Open 0.0160
  • Bid 0.0160 x 5745900
  • Ask 0.0170 x 1100000
  • Day's Range 0.0160 - 0.0170
  • 52 Week Range 0.0020 - 0.0550
  • Volume 15,903
  • Avg. Volume 116,975
  • Market Cap (intraday) 5.449M
  • Beta (5Y Monthly) 2.75
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Numinus Wellness Inc. provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States. The company operates through Clinical Research Operations and Practitioner Training segments. It also provides clinical research management services to academic institutions and biotechnology companies. In addition, the company engages in the provision of education and training for research and drug development organizations to support clinical trials and commercialization efforts. The company serves biotechnology and pharmaceutical companies, research institutions, and healthcare professionals. The company was formerly known as Salvation Botanicals Ltd. and changed its name to Numinus Wellness Inc. in May 2020. Numinus Wellness Inc. is headquartered in Vancouver, Canada.

www.numinusnetwork.com

--

Full Time Employees

August 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NUMIF
43.33%
S&P 500 (^GSPC)
11.07%

1-Year Return

NUMIF
58.54%
S&P 500 (^GSPC)
11.16%

3-Year Return

NUMIF
83.33%
S&P 500 (^GSPC)
76.09%

5-Year Return

NUMIF
97.21%
S&P 500 (^GSPC)
64.19%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY24
Revenue 4.35M
Earnings -5.76M
Profit Margin -132.34%

Q4

FY23

Q1

FY24

Q2

FY24

Q3

FY24

-5M
0
5M
-140.0%
-120.0%
-100.0%
-80.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    102.07%

  • Return on Assets (ttm)

    -20.54%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    6.85M

  • Net Income Avi to Common (ttm)

    5.42M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    447.31k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    1.36M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: